Protein vaccination with HPV16 E7/Pep‐1 nanoparticles elicits a protective T‐helper cell‐mediated immune response

Mardani, Golnaz; Bolhassani, Azam; Agi, Elnaz; Shahbazi, Sepideh; Sadat, Seyed Mehdi

doi:10.1002/iub.1503

Cited by 22 publications

(10 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study, our group used Pep-1 for in vitro and in vivo delivery of HPV16 E7 protein as a tumor antigen. Our data indicated that E7/Pep-1 nanoparticles in a certain molar ratio of 1: 20 induced Th1 immune responses and protected mice against TC-1 tumor cells similar to the group immunized with E7 emulsified with Freund adjuvant (~80% tumor-free mice) [262]. Moreover, priming with HIV-1 MPER-V3 DNA/MPG nanoparticles at N/P ratio of 1:10 followed by MPER +V3 peptides as boosting could direct T cell immune responses toward a Th1-type [263].…”

Section: Vaccinesupporting

confidence: 56%

Cell penetrating peptides: the potent multi-cargo intracellular carriers

Kardani

Milani

Shabani

et al. 2019

Expert Opinion on Drug Delivery

Self Cite

146

View full text Add to dashboard Cite

Introduction: Cell penetrating peptides (CPPs) known as protein translocation domains (PTD), membrane translocating sequences (MTS), or Trojan peptides (TP) are able to cross biological membranes without clear toxicity using different mechanisms, and facilitate the intracellular delivery of a variety of bioactive cargos. CPPs could overcome some limitations of drug delivery and combat resistant strains against a broad range of diseases. Despite delivery of different therapeutic molecules by CPPs, they lack cell specificity and have a short duration of action. These limitations led to design of combined cargo delivery systems and subsequently improvement of their clinical applications. Areas covered: This review covers all our studies and other researchers in different aspects of CPPs such as classification, uptake mechanisms, and biomedical applications. Expert opinion: Due to low cytotoxicity of CPPs as compared to other carriers and final degradation to amino acids, they are suitable for preclinical and clinical studies. Generally, the efficiency of CPPs was suitable to penetrate the cell membrane and deliver different cargos to specific intracellular sites. However, no CPP-based therapeutic approach has approved by FDA, yet; because there are some disadvantages for CPPs including short half-life in blood, and nonspecific CPP-mediated delivery to normal tissue. Thus, some methods were used to develop the functions of CPPs in vitro and in vivo including the augmentation of cell specificity by activatable CPPs, specific transport into cell organelles by insertion of corresponding localization sequences, incorporation of CPPs into multifunctional dendrimeric or liposomal nanocarriers to improve selectivity and efficiency especially in tumor cells.

show abstract

Section: Vaccinesupporting

confidence: 56%

Cell penetrating peptides: the potent multi-cargo intracellular carriers

Kardani

Milani

Shabani

et al. 2019

Expert Opinion on Drug Delivery

Self Cite

146

View full text Add to dashboard Cite

show abstract

“…For example, Mardani et al . developed a nanoparticle-based HPV vaccine incorporating Pep-1 peptide [115]. E7 protein/Pep-1 peptide complex was mixed at a ratio of 1/20 to form nanoparticles with average diameters ranging from 120 to 250 nm.…”

Section: Applications Of Cpps In Vaccine Deliverymentioning

confidence: 99%

Cell-penetrating Peptides: Efficient Vectors for Vaccine Delivery

Yang

Luo

Shibu

et al. 2019

CDD

View full text Add to dashboard Cite

Subunit vaccines are composed of pathogen fragments that, on their own, are generally poorly immunogenic. Therefore, the incorporation of an immunostimulating agent, e.g. adjuvant, into vaccine formulation is required. However, there are only a limited number of licenced adjuvants and their immunostimulating ability is often limited, while their toxicity can be substantial. To overcome these problems, a variety of vaccine delivery systems have been proposed. Most of them are designed to improve the stability of antigen in vivo and its delivery into immune cells. Cell-penetrating peptides (CPPs) are especially attractive component of antigen delivery systems as they have been widely used to enhance drug transport into the cells. Fusing or co-delivery of antigen with CPPs can enhance antigen uptake, processing and presentation by antigen presenting cells (APCs), which are the fundamental steps in initiating an immune response. This review describes the different mechanisms of CPP intercellular uptake and various CPP-based vaccine delivery strategies.

show abstract

“…2 ). This was directly demonstrated using Zebra-derived CPPs, TAT, and penetratin [ 16 , 22 , 24 , 46 , 54 , 55 ].…”

Section: Multi-epitopic Antigenic Cargosmentioning

confidence: 99%

Mechanistic insights into the efficacy of cell penetrating peptide-based cancer vaccines

Grau¹,

Walker

Derouazi³

2018

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

Immunotherapies are increasingly used to treat cancer, with some outstanding results. Immunotherapy modalities include therapeutic vaccination to eliminate cancer cells through the activation of patient’s immune system against tumor-derived antigens. Nevertheless, the full potential of therapeutic vaccination has yet to be demonstrated clinically because many early generation vaccines elicited low-level immune responses targeting only few tumor antigens. Cell penetrating peptides (CPPs) are highly promising tools to advance the field towards clinical success. CPPs efficiently penetrate cell membranes, even when linked to antigenic cargos, which can induce both CD8 and CD4 T-cell responses. Pre-clinical studies demonstrated that targeting multiple tumor antigens, even those considered to be poorly immunogenic, led to tumor regression. Therefore, CPP-based cancer vaccines represent a flexible and powerful means to extend therapeutic vaccination to many cancer indications. Here, we review recent findings in CPP development and discuss their use in next generation immunotherapies.

show abstract

Protein vaccination with HPV16 E7/Pep‐1 nanoparticles elicits a protective T‐helper cell‐mediated immune response

Cited by 22 publications

References 48 publications

Cell penetrating peptides: the potent multi-cargo intracellular carriers

Cell penetrating peptides: the potent multi-cargo intracellular carriers

Cell-penetrating Peptides: Efficient Vectors for Vaccine Delivery

Mechanistic insights into the efficacy of cell penetrating peptide-based cancer vaccines

Contact Info

Product

Resources

About